Update on therapeutic options in Waldenström macroglobulinemia

European Journal of Haematology

Volumn 82, Issue 1, 2009, Pages 1-12

  Leleu, Xavier ^a,b   Gay, Julie ^a   Roccaro, Aldo M ^b,c   Moreau, Anne Sophie ^a,b   Poulain, Stephanie ^d   Dulery, Remy ^a   Champs, Berenice Bro Des ^a   Robu, Daniela ^a   Ghobrial, Irene M ^b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF BRESCIA   (Italy)

^d CENTRE HOSPITALIER DE VALENCIENNES   (France)

Author keywords

Novel therapy; Waldenstr m macroglobulinemia

Indexed keywords

ALEMTUZUMAB; BORTEZOMIB; CARMUSTINE; CHLORAMBUCIL; CLADRIBINE; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ENZASTAURIN; ETOPOSIDE; EVEROLIMUS; FLUDARABINE; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN M; IODINE 131; LENALIDOMIDE; MELPHALAN; PERIFOSINE; PR 171; PREDNISONE; PROTEASOME INHIBITOR; RITUXIMAB; SALINOSPORAMIDE A; THALIDOMIDE; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE; YTTRIUM 90;

ACUTE LEUKEMIA; ALLOGENIC BONE MARROW TRANSPLANTATION; ANEMIA; ARTHRITIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; B LYMPHOCYTE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HUMAN; IMMUNE DEFICIENCY; INFECTION; LYMPHOCYTIC INFILTRATION; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA AND VOMITING; NEUROTOXICITY; NEUTROPENIA; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; REVIEW; SENSORY NEUROPATHY; SPLENECTOMY; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA;

ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOTHERAPY; SIGNAL TRANSDUCTION; WALDENSTROM MACROGLOBULINEMIA;

EID: 57649213386     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2008.01171.x     Document Type: Review

References (97)

1. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003 30 : 110 5.
2. Herrinton LJ, Weiss NS. Incidence of Waldenstrom's macroglobulinemia. Blood 1993 82 : 3148 50.
3. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005 55 : 10 30.
4. Ghobrial IM, Gertz MA, Fonseca R. Waldenstrom macroglobulinaemia. Lancet Oncol 2003 4 : 679 85.
5. Ghobrial IM, Fonseca R, Gertz MA, Plevak MF, Larson DR, Therneau TM, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006 133 : 158 64.
6. Benjamin M, Reddy S, Brawley OW. Myeloma and race: a review of the literature. Cancer Metastasis Rev 2003 22 : 87 93.
7. McMaster ML. Familial Waldenstrom's macroglobulinemia. Semin Oncol 2003 30 : 146 52.
8. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Semin Oncol 2003 30 : 169 71.
9. Morra E, Cesana C, Klersy C, Barbarano L, Varettoni M, Cavanna L, et al. Clinical characteristics and factors predicting evolution of asymptomatic IgM monoclonal gammopathies and IgM-related disorders. Leukemia 2004 18 : 1512 7.
10. Kyle RA, Treon SP, Alexanian R, Barlogie B, Bjorkholm M, Dhodapkar M, et al. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003 30 : 116 20.
11. Kriangkum J, Taylor BJ, Treon SP, Mant MJ, Belch AR, Pilarski LM. Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood. Blood 2004 104 : 2134 42.
12. Schop RF, Van Wier SA, Xu R, Ghobrial I, Ahmann GJ, Greipp PR, et al. 6q deletion discriminates Waldenstrom macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet 2006 169 : 150 3.
13. Avet-Loiseau H, Garand R, Lode L, Robillard N, Bataille R. 14q32 Translocations discriminate IgM multiple myeloma from Waldenstrom's macroglobulinemia. Semin Oncol 2003 30 : 153 5.
14. Ocio EM, Schop RF, Gonzalez B, Van Wier SA, Hernandez-Rivas JM, Gutierrez NC, et al. 6q deletion in Waldenstrom macroglobulinemia is associated with features of adverse prognosis. Br J Haematol 2007 136 : 80 6.
15. Remstein ED, Hanson CA, Kyle RA, Hodnefield JM, Kurtin PJ. Despite apparent morphologic and immunophenotypic heterogeneity, Waldenstrom's macroglobulinemia is consistently composed of cells along a morphologic continuum of small lymphocytes, plasmacytoid lymphocytes, and plasma cells. Semin Oncol 2003 30 : 182 6.
16. San Miguel JF, Vidriales MB, Ocio E, Mateo G, Sanchez-Guijo F, Sanchez ML, et al. Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol 2003 30 : 187 95.
17. Ocio EM, Hernandez JM, Mateo G, Sanchez ML, Gonzalez B, Vidriales B, et al. Immunophenotypic and cytogenetic comparison of Waldenstrom's macroglobulinemia with splenic marginal zone lymphoma. Clin Lymphoma 2005 5 : 241 5.
18. Fonseca R, Hayman S. Waldenstrom macroglobulinaemia. Br J Haematol 2007 138 : 700 20.
19. Vijay A, Gertz MA. Waldenstrom macroglobulinemia. Blood 2007 109 : 5096 103.
20. Pangalis GA, Kyrtsonis MC, Kontopidou FN, Siakantaris MP, Dimopoulou MN, Vassilakopoulos TP, et al. Differential diagnosis of Waldenstrom's macroglobulinemia and other B-cell disorders. Clin Lymphoma 2005 5 : 235 40.
21. Merlini G, Baldini L, Broglia C, Comelli M, Goldaniga M, Palladini G, et al. Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. Semin Oncol 2003 30 : 211 5.
22. Dimopoulos MA, Hamilos G, Zervas K, Symeonidis A, Kouvatseas G, Roussou P, et al. Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia. Ann Oncol 2003 14 : 1299 305.
23. Morel P, Duhamel A, Gobbi P, et al. International Prognostic Scoring System (IPSS) for Waldenström's Macroglobulinemia (WM). Blood 2006 108 : 42a. (ASH Annual Meeting Abstracts). (abs. 127)
24. Leleu X, Moreau AS, Weller E, Roccaro AM, Coiteux V, Manning R, et al. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma 2008 49 : 1104 7.
25. Ho A, Leleu X, Hatjiharissi E, et al. A novel functional role for soluble CD27 in the pathogenesis of Waldenstrom's macroglobulinemia. Blood 2005 106 : 225b. (ASH Annual Meeting Abstracts) (abs. 4701).
26. Treon SP, Gertz MA, Dimopoulos M, Anagnostopoulos A, Blade J, Branagan AR, et al. Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood 2006 107 : 3442 6.
27. Kimby E, Treon SP, Anagnostopoulos A, Dimopoulos M, Garcia-Sanz R, Gertz MA, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma 2006 6 : 380 3.
28. Treon SP, Hatjiharissi E, Leleu X, Moreau AS, Roccaro A, Hunter ZR, et al. Novel agents in the treatment of Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2007 7 (Suppl. 5 S199 206.
29. Leleu X, Roccaro AM, Moreau AS, Dupire S, Robu D, Gay J, et al. Waldenstrom macroglobulinemia. Cancer Lett 2008 270 : 95 107.
30. Dimopoulos MA, O'Brien S, Kantarjian H, Estey EE, Keating MJ, Alexanian R. Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues. Leuk Lymphoma 1993 11 (Suppl. 2 105 8.
31. Leblond V, Levy V, Maloisel F, Cazin B, Fermand JP, Harousseau JL, et al. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenstrom macroglobulinemia in first relapse or with primary refractory disease. Blood 2001 98 : 2640 4.
32. Weber DM, Dimopoulos MA, Delasalle K, Rankin K, Gavino M, Alexanian R. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia. Semin Oncol 2003 30 : 243 7.
33. Leleu X, Manning R, Soumerai J, et al. Increased incidence of disease transformation and development of MDS/AML in Waldenstrom's macroglobulinemia (WM) patients treated with nucleoside analogues. J Clin Oncol 2007 25 : 445s. (ASCO Annual Meeting Proceedings Part I).
34. Uchino K, Sameshima H, Miyamoto T, Iino T, Kato K, Henzan H, et al. Successful treatment of diffuse large B-cell lymphoma following Waldenstrom's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab. Intern Med 2004 43 : 131 4.
35. Dimopoulos MA, Zervas C, Zomas A, Hamilos G, Gika D, Efstathiou E, et al. Extended rituximab therapy for previously untreated patients with Waldenstrom's macroglobulinemia. Clin Lymphoma 2002 3 : 163 6.
36. Gertz MA, Rue M, Blood E, Kaminer LS, Vesole DH, Greipp PR. Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004 45 : 2047 55.
37. Dimopoulos MA, Alexanian R, Gika D, Anagnostopoulos A, Zervas C, Zomas A, et al. Treatment of Waldenstrom's macroglobulinemia with rituximab: prognostic factors for response and progression. Leuk Lymphoma 2004 45 : 2057 61.
38. Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, et al. Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 2005 23 : 474 81.
39. Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole DH, et al. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 2004 101 : 2593 8.
40. Van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006 108 : 3295 301.
41. Zivkovic SA. Rituximab in the treatment of peripheral neuropathy associated with monoclonal gammopathy. Expert Rev Neurother 2006 6 : 1267 74.
42. Dimopoulos MA, Hamilos G, Efstathiou E, Siapkaras I, Matsouka C, Gika D, et al. Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma 2003 44 : 993 6.
43. Tamburini J, Levy V, Chaleteix C, Fermand JP, Delmer A, Stalniewicz L, et al. Fludarabine plus cyclophosphamide in Waldenstrom's macroglobulinemia: results in 49 patients. Leukemia 2005 19 : 1831 4.
44. Tam CS, Wolf M, Prince HM, Januszewicz EH, Westerman D, Lin KI, et al. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma. Cancer 2006 106 : 2412 20.
45. Buske C, Dreyling M, Eimermacher H. Combined immuno-chemotherapy (R-CHOP) results in significantly superior response rates and time to treatment of patients with lymphoplasmocytoid/ic immunocytoma (LP-IC): results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 2004 104 : 50a. (abstract 162).
46. Treon SP, Hunter Z, Barnagan AR. CHOP plus rituximab therapy in Waldenstrom's macroglobulinemia. Clin Lymphoma 2005 5 : 273 7.
47. Abonour R, Zhang L, Rajkumar V, Srkalovic G, Greipp P, Fonseca R, et al. Phase II pilot study of rituximab + CHOP in patients with newly diagnosed WM, an ECOG Study (E1A02). Blood 2007 110 : 00. (Abstract 3616).
48. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Zervas K, Tsatalas C, Kokkinis G, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007 25 : 3344 9.
49. Kyle RA, Greipp PR, Gertz MA, Witzig TE, Lust JA, Lacy MQ, et al. Waldenstrom's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000 108 : 737 42.
50. Rodriguez JN, Fernandez-Jurado A, Martino ML, Prados D. Waldenstrom's macroglobulinemia complicated with acute myeloid leukemia. Report of a case and review of the literature. Haematologica 1998 83 : 91 2.
51. Martinelli G, Laszlo D, Bertolini F, Pastano R, Mancuso P, Calleri A, et al. Chlorambucil in combination with induction and maintenance rituximab is feasible and active in indolent non-Hodgkin's lymphoma. Br J Haematol 2003 123 : 271 7.
52. Desikan R, Dhodapkar M, Siegel D, Fassas A, Singh J, Singhal S, et al. High-dose therapy with autologous haemopoietic stem cell support for Waldenstrom's macroglobulinaemia. Br J Haematol 1999 105 : 993 6.
53. Dreger P, Glass B, Kuse R, Sonnen R, von Neuhoff N, Bolouri H, et al. Myeloablative radiochemotherapy followed by reinfusion of purged autologous stem cells for Waldenstrom's macroglobulinaemia. Br J Haematol 1999 106 : 115 8.
54. Anagnostopoulos A, Dimopoulos MA, Aleman A, Weber D, Alexanian R, Champlin R, et al. High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenstrom's macroglobulinemia. Bone Marrow Transplant 2001 27 : 1027 9.
55. Tournilhac O, Leblond V, Tabrizi R, Gressin R, Senecal D, Milpied N, et al. Transplantation in Waldenstrom's macroglobulinemia - the French experience. Semin Oncol 2003 30 : 291 6.
56. Anagnostopoulos A, Hari PN, Perez WS, Ballen K, Bashey A, Bredeson CN, et al. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. Biol Blood Marrow Transplant 2006 12 : 845 54.
57. Roccaro AM, Vacca A, Ribatti D. Bortezomib in the treatment of cancer. Recent Patents Anticancer Drug Discov 2006 1 : 397 403.
58. Treon SP, Hunter ZR, Matous J, Joyce RM, Mannion B, Advani R, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248. Clin Cancer Res 2007 13 : 3320 5.
59. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, Castritis E, Bitsaktsis A, Pangalis GA. Treatment of relapsed or refractory Waldenstrom's macroglobulinemia with bortezomib. Haematologica 2005 90 : 1655 8.
60. Chen CI, Kouroukis CT, White D, Voralia M, Stadtmauer E, Stewart AK, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007 25 : 1570 5.
61. Roccaro AM, Leleu X, Sacco A, Jia X, Melhem M, Moreau AS, et al. Dual targeting of the proteasome regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2008 111 : 4752 63.
62. O'Connor OA, Ormowski RZ, Alsina M, et al. Multicenter phase I studies to evaluate the safety, tolerability, and clinical response to intensive dosing with the proteasome inhibitor PR-171 in patients with relapsed or refractory hematological malignancies. Blood 2006 108 : 687a. (abs. 2430).
63. Treon SP, Iokamidis L, Soumerai JD, Patterson CJ, Hunter ZR, Feiner A, et al. Primary therapy of Waldenstrom's macroglobulinemia with bortezomib, dexamethasone and rituximab: results of WMCTG clinical trial 05-180. J Clin Oncol 2008 26 : 18s. (abs 8519).
64. Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006 108 : 3458 64.
65. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001 98 : 492 4.
66. Dimopoulos MA, Tsatalas C, Zomas A, Hamilos G, Panayiotidis P, Margaritis D, et al. Treatment of Waldenstrom's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone. Semin Oncol 2003 30 : 265 9.
67. Treon SPSJ, Branagan AR, Hunter ZR, et al. Thalidomide and rituximab in Waldenstrom's macroglobulinemia. Blood 2008 112 : 4452 7.
68. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001 98 : 210 6.
69. Owen RG, Hillmen P, Rawstron AC. CD52 expression in Waldenstrom's macroglobulinemia: implications for alemtuzumab therapy and response assessment. Clin Lymphoma 2005 5 : 278 81.
70. Santos DD, Hatjiharissi E, Tournilhac O, Chemaly MZ, Leleu X, Xu L, et al. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's macroglobulinemia and mast cell disorders. Clin Lymphoma Myeloma 2006 6 : 478 83.
71. Hunter Z, Boxer M, Kahl B, Patterson CJ, Soumerai JD, Treon SP. Phase II study of alemtuzumab in lymphoplasmacytic lymphoma: results of WMCTG trial 02-079. J Clin Oncol 2006 24 : 427.
72. Tsai DE, Maillard I, Downs LH, Alavi A, Nasta SD, Glatstein E, et al. Use of iodine 131I-tositumomab radioimmunotherapy in a patient with Waldenstrom's macroglobulinemia. Leuk Lymphoma 2004 45 : 591 5.
73. Leleu X, Jia X, Runnels J, Ngo HT, Moreau AS, Farag M, et al. The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood 2007 110 : 4417 26.
74. Leleu X, Eeckhoute J, Jia X, Roccaro AM, Moreau AS, Farag M, et al. Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood 2008 111 : 5068 77.
75. Hatjiharissi E, Ngo H, Leontovich AA, Leleu X, Timm M, Melhem M, et al. Proteomic analysis of Waldenstrom macroglobulinemia. Cancer Res 2007 67 : 3777 84.
76. Moreau AS, Jia X, Ngo HT, Leleu X, O'Sullivan G, Alsayed Y, et al. Protein kinase C inhibitor enzastaurin induces in vitro and in vivo antitumor activity in Waldenstrom macroglobulinemia. Blood 2007 109 : 4964 72.
77. Younes H, Leleu X, Hatjiharissi E, Moreau AS, Hideshima T, Richardson P, et al. Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma. Clin Cancer Res 2007 13 : 3771 5.
78. Richardson P, Lonial S, Jakubowiak A, et al. Multi-center phase II study of Perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM): promising activity as combination therapy with manageable toxicity. Blood 2007 110 : 353a. (abs.1164).
79. Ghobrial IM, Leleu X, Rubin N, Leduc R, Chuma S, Nelson M, Sportelli P, Richardson PG, Treon SP, Anderson KC. Phase II trial of the novel oral Akt inhibitor perifosine in relapsed and/or refractory Waldenstrom macroglobulinemia (WM). J Clin Oncol 2008 26 : 18s. (abstract 8546).
80. Ghobrial I, Leduc R, Nelson M, et al. Phase II trial of the oral mTOR inhibitor RAD001 (Everolimus) in relapsed and/or refractory Waldenstrom macroglobulinemia: preliminary results. Blood 2007 110 : 11. (ASH Annual Meeting Abstracts) (abs.4496).
81. Soumerai J, O'Connor KE, Ioakimidis LM, et al. Imatinib mesylate (Gleevec) produces responses in patients with relapsed/refractory Waldenstroms macroglobulinemia. Blood 2007 110 : 2575. (ASH Annual Meeting Abstracts).
82. Frankel SR. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis. Semin Oncol 2003 30 : 300 4.
83. Nichols GL, Stein CA. Modulation of the activity of Bcl-2 in Waldenstrom's macroglobulinemia using antisense oligonucleotides. Semin Oncol 2003 30 : 297 9.
84. Gertz MA, Geyer SM, Badros A, Kahl BS, Erlichman C. Early results of a phase I trial of oblimersen sodium for relapsed or refractory Waldenstrom's macroglobulinemia. Clin Lymphoma 2005 5 : 282 4.
85. Ho AW, Hatjiharissi E, Ciccarelli BT, et al. CD27-CD70 interactions in the pathogenesis of Waldenstrom's macroglobulinemia. Blood 2008 (in press).
86. Klein B, Tarte K, Jourdan M, Mathouk K, Moreaux J, Jourdan E, et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 2003 78 : 106 13.
87. Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood 2005 106 : 1021 30.
88. Rossi J, Moreaux J, Rose M, Picard M, Ythier A, Rossier C, Sievers E, Klein BA. Phase I/II study of Atacicept (TACI-Ig) to neutralize APRIL and BLyS in patients with refractory or relapsed multiple myeloma (MM) or active previously treated Waldenstrom's macroglobulinemia (WM). Blood 2006 108 : 3578. (ASH Annual Meeting Abstracts).
89. Kundu JK, Surh YJ. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett 2008 269 : 243 61.
90. Roccaro AM, Leleu X, Sacco A, Moreau AS, Hatjiharissi E, Jia X, et al. Resveratrol exerts antiproliferative activity and induces apoptosis in Waldenstrom's macroglobulinemia. Clin Cancer Res 2008 14 : 1849 58.
91. Patterson CJ, Soumerai J, Hunter ZR, et al. Sildenafil citrate suppresses disease progression in patients with Waldenstrom's macroglobulinemia. J Clin Oncol 2006 24 : 435s. (abs 7556).
92. Treon SP, Tournilhac O, Branagan AR, Hunter Z, Xu L, Hatjiharissi E, et al. Clinical responses to sildenafil in Waldenstrom's macroglobulinemia. Clin Lymphoma 2004 5 : 205 7.
93. Ngo HT, Leleu X, Lee J, Jia X, Melhem M, Runnels J, et al. SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia. Blood 2008 112 : 150 8.
94. Brookes PS, Morse K, Ray D, Tompkins A, Young SM, Hilchey S, et al. The triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid and its derivatives elicit human lymphoid cell apoptosis through a novel pathway involving the unregulated mitochondrial permeability transition pore. Cancer Res 2007 67 : 1793 802.
95. Moreau AS, Jia X, Patterson CJ, et al. The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. Br J Haematol 2008 (in press).
96. Tam CS, Wolf MM, Westerman D, Januszewicz EH, Prince HM, Seymour JF. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2005 6 : 136 9.
97. Hensel M, Villalobos M, Kornacker M, Krasniqi F, Ho AD. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. Clin Lymphoma Myeloma 2005 6 : 131 5.